Shares of BioAge Labs (BIOA), a biopharmaceutical company focused on obesity drugs, opened 25% above its initial public ...

A woman who started taking a popular weight loss medication through a clinical trial had to look for alternatives when her ...

Weight-loss drug developer BioAge Labs (BIOA) on Wednesday announced the pricing of its upsized initial public offering of 11 ...

The arrival of GLP-1 analog drugs (such as Wegovy) marked a huge shift in the weight-loss drug market. These drugs have been ...

James Corden revealed that he gave Ozempic a try to help with weight loss, but soon found that his relationship with food had ...

An emerging market for compounded weight loss injections that mimic brand-name drugs such as Ozempic, Wegovy, Mounjaro and ...

Shares of BioAge Labs opened 25% above their initial public offering price on Thursday in a strong debut for the weight-loss drug developer against the backdrop of surging investor enthusiasm.

five times that on the brand name drug,” Noom CEO Geoff Cook said of the prices for his company’s compounded semaglutide.

Wegovy is a once-weekly injection approved by the U.S. Food and Drug Administration (FDA) to treat obesity in people 12 and ...

James Corden revealed that he gave Ozempic a try to help with weight loss, but soon found that his relationship with food had little to do with how hungry he was or wasn't.

The surging popularity of weight-loss drugs, expected to be a $150 billion market by early 2030s, has whetted investor appetite in companies looking to tap into the boom. BioAge priced its offering of ...

Results of the human clinical trial will be shared with LifeVantage Consultants at Market Connect in Kansas City, October ...